05:49 AM EDT, 05/10/2024 (MT Newswires) -- PDS Biotechnology ( PDSB ) said late Thursday its experimental therapy to treat a type of head and neck cancer in combination with Merck's Keytruda met the primary study endpoints in a phase 2 clinical trial.

The data from the study showed that the combination therapy was well tolerated among patients, with 30 month median overall survival, the company said.

PDS Biotechnology ( PDSB ) plans to initiate a phase 3 registrational trial in 2024.

Price: 4.1500, Change: +0.32, Percent Change: +8.36